Management of Metastatic Melanoma 2005

Surgical Oncology Clinics of North America

Volumn 15, Issue 2, 2006, Pages 419-437

  O'Day, Steven ^a,b   Boasberg, Peter ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; FOTEMUSTINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDRAZIDE DERIVATIVE; INTERLEUKIN 2; LOMUSTINE; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO 95; MONOCLONAL ANTIBODY CP 675 206; MONOCLONAL ANTIBODY LM 609; MONOCLONAL ANTIBODY MDX 010; OBLIMERSEN; PACLITAXEL; SORAFENIB; STA 4783; TALABOSTAT; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DERMATITIS; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EDEMA; ENZYME INHIBITION; FATIGUE; GLIOMA; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MELANOMA; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PROTEIN SECRETION; REVIEW; THROMBOCYTOPENIA; THYROIDITIS; VITILIGO; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 33745610210     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2005.12.002     Document Type: Review

References (115)

1. Balch C.M. Cutaneous melanoma. Prognosis and treatment results worldwide. Semin Surg Oncol 8 (1992) 400-414
2. Balch C.M., Soon S.J., and Murad T.M. A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases. J Clin Oncol 1 (1983) 126-134
3. Barth A., Warnek L.A., and Morton D.L. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181 (1995) 192-201
4. Joseph W.L., Morton D.L., and Adkins P.C. Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg 61 (1971) 23-32
5. Morton D.L., Ollila D.W., Hsueh E.C., et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 49 2 (1999) 101-116 65
6. Morton DL, Hsueh EC, Ollila DW, et al. Cytoreductive surgery and adjuvant postoperative immunotherapy with polyvalent melanoma vaccine enhances survival for stage IV melanoma: results of matched-pair analysis. Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 1417.
7. Morton DL, Essner R, Hsueh EC, et al. Active specific immunotherapy with a polyvalent cancer vaccine prolongs survival in AJCC stage IV melanoma. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2543.
8. Wornom III I.L., Smith J.W., Soon S.J., et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 204 2 (1986) 181-185
9. Ollila D.W., Essner R., Wanek L.A., et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 131 9 (1996) 975-980
10. Brega K., Robinson W.A., Winston K., et al. Surgical treatment of brain metastases in malignant melanoma. Cancer 66 10 (1990) 2105-2110
11. Tsioulas GT, Boasberg PD, O'Day SJ, et al. Salvage metastasectomy improves survival in stage IV melanoma patients treated with concurrent biochemotherapy. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12-15, 2001; San Francisco, Calif. Abstract 1440.
12. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. Clin Oncol 2001;15;19(16):3635-48.
13. O'Day SJ, Atkins M, Weber J, et al. A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7503.
14. Kirkwood JM, Bedikian AY, Millward J, et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7506.
15. Anderson C., Buzaid A., and Legha S. Systemic treatments for advanced cutaneous melanoma. Oncology 9 (1995) 1149-1158
16. Hill II G.J., Krementz E.T., and Hill H.Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53 (1984) 1299-1305
17. Anderson C., Buzaid A., and Legha S. Systemic treatments for advanced cutaneous melanoma. Oncology 9 (1995) 1149-1158
18. Ahmann D.L., Hahn R., and Bisel H. Evaluation of 1-(2 chloro-ethyl-3,4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU, NSC 95411) versus combined imidazole carboxamide (NSC 45388) and vincristine (NSC 67574) in palliation of disseminated malignant melanoma. Cancer 33 (1974) 615-618
19. Atkins M.B. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood J.K. (Ed). Molecular diagnosis, prevention & therapy of melanoma (1997), Marcel Dekker, New York 219
20. Glover D., Glick J.H., Weiler C., et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5 (1987) 574-578
21. Einzig A., Hochster H., Wiernik P., et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 9 1 (1991) 59-64
22. Legha S.S., Ring S., Papadopoulos N., et al. A phase II trial of taxol in metastatic melanoma. Cancer 65 11 (1990) 2478-2481
23. Einzig A, Schuchter LM, Wadler S, et al. Phase II trial of Taxotere (RP 56976) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology; May 14-17, 1994; Dallas, Tex. Abstract 1345.
24. Bedikian A.Y., Weiss G.R., Legha S.S., et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 13 12 (1995) 2895-2899
25. Millward MJ, Bedikian AY, Conry RM, et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of long-term survival. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 7505.
26. Millward MJ, Bedikian AY, Conry RM, et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of long-term survival. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 7505.
27. Wagner S, Weber J, Redman B, et al. CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: a randomized phase II trial comparing two doses and in combination with DTIC. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7526.
28. Crosby T., Fish R., Coles B., et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2 (2000) CD001215
29. Patel M, McCully C, Godwin K, et al. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology, May 20-23, Los Angeles, Calif. Abstract 1485.
30. Freeman H.S., Kerby T., and Calvert H. Temozolomide and the treatment of malignant gliomas. Clin Cancer Res 6 (2000) 2585
31. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced, metastatic melanoma. J Clin Oncol 18 1 (2000) 158-166
32. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Canc Res 58 (1998) 4363
33. Hwu W.J., Raizer J., Panageas K.S., et al. Treatment of metastatic melanoma in the brain with Temozolomide and thalidomide. Lancet Oncol 2 (2001) 634-635
34. Atkins MB, Sosman J, Agarwala S, et al. A cytokine working group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7552.
35. Stupp R, Mason WP, Van Den Bent JM, et al. Concomitant and adjuvant Temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain and RT Groups and NCIC Clinical Trials Group. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 2.
36. Khayat D., Avril M., Auelere G., et al. Clinical value of the nitrosourea fotemustine in disseminated malignant melanoma: overview of 1022 patients including 144 patients with cerebral metastases. Proceedings of the American Society of Clinical Oncology 12 (1993) 393 Abstract 1343
37. Jacquillat C., Khayat D., Banzet P., et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66 2 (1990) 1873-1878
38. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22 6 (2004) 1118-1125
39. Mornex F., Thomas L., Mohr P., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13 1 (2003) 97-103
40. Costanzi J.J., Vaitkevicius V.K., Quagliana J.M., et al. Combination chemotherapy for disseminated melanoma. Cancer 35 2 (1975) 342-346
41. Seigler H.F., Lucas Jr. V.S., Pickett N.J., et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 46 11 (1980) 2346-2348
42. Feun L, Savaraj N, Hurley J, et al. Phase II trial of taxol and DTIC with filgrastim administration in advanced malignant melanoma - final report. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; May 20-23, 2000; New Orleans, La. Abstract 2252.
43. Restas S., Mohith A., and Mackenzie H. TAXOL and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs 7 (1996) 161
44. Hodi F.S., Soiffer R.J., Clark J., et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25 3 (2002) 283-386
45. Nathan F.E., Berd D., Sato T., et al. Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma. Cancer 88 (2000) 79
46. Bafaloukos D., Gogas H., Georgoulias V., et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 20 2 (2002) 420-425
47. Murren J.R., DeRosa W., Durivage H.J., et al. High dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 67 6 (1991) 1514-1517
48. Legha S.S., Ring S., Papadopoulos N., et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64 10 (1989) 2024-2029
49. Del Prete S., Maurer L.H., O'Donnoll J., et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68 11 (1984) 1403-1405
50. Buzaid AC, Legha S, Winn R, et al. Cisplatin, vinblastine, and dacarbazine versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; May 16-18, 1993; Orlando, Fla. Abstract 1328.
51. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2745-2751
52. Fisher R., Neifeld J., and Lippman M. Oestrogen receptors in human malignant melanoma. Lancet 2 7981 (1976) 337-339
53. Rumke P., Kleeberg U.R., MacKie R.M., et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res 2 3 (1992) 153-156
54. McClay E.F., and McClay M.E. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?. J Clin Oncol 12 3 (1994) 617-626
55. McClay E.F., Albright K.D., Jones J.A., et al. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53 7 (1993) 1571-1576
56. Kirk J., Syed S.K., Harris A.L., et al. Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol 48 2 (1994) 277-285
57. Cocconi G., Bella M., Calabresi F., et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327 8 (1992) 516-523
58. Legha S, Ring S, Bedikian A, et al. Lack of benefit from tamoxifen added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and alpha interferon (IFN) in patients with metastatic melanoma. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; May 16-18, 1993; Orlando, Fla. Abstract 1325.
59. Agarwala S.S., Ferri W., Gooding W., et al. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 85 9 (1999) 1979-1984
60. Rusthoven J.J., Quirt I.C., Iscoe N.A., et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14 7 (1996) 2083-2090
61. Falkson C.I., Ibrahim J., Kirkwood J.M., et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16 5 (1998) 1743-1751
62. Hollenbeak C.S., Todd M.M., Billingsley E.M., et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 104 9 (2005) 1962-1967
63. Norlund J.J., Kirkwood J.M., Forget B.M., et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9 5 (1983) 689-696
64. Bystryn J.C., Rigel D., Friedman R.J., et al. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123 (1987) 1053-1055
65. Phan G.Q., Attia P., Steinberg S.M., et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19 15 (2001) 3477-3482
66. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
67. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 19 4 (2001) 1226-1228
68. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
69. Urba W.J., Steis R.G., Longo D.L., et al. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res 50 1 (1990) 185-192
70. Schwartzentruber D.J., and Rosenberg S.A. Interleukins. In: Balch C.M., Houghton A.N., Sober A.J., et al. (Eds). Cutaneous melanoma. 4th edition (2003), Quality Medical Publishing, Inc., St. Louis (MO) 623-636
71. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999) 2105
72. Richards J.M., Mehta N., Ramming K., et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10 (1992) 1338-1343
73. Khayat D., Borel C., Tourani J.M., et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11 (1993) 2173-2180
74. Legha S.S., Ring S., Eton O., et al. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center Experience. Cancer J Sci Am 3 (1997) S9-S15
75. Legha S.S., Ring S., Bedikian A., et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7 (1996) 827-835
76. Allen I.E., Kupelnick B., and Kumashiro M. Efficacy of interleukin-2 in the treatment of metastatic melanoma-systemic review and metastasis-analysis. Cancer Ther 1 (1998) 168-173
77. Keiholtz U., Contradt C., Legha S.S., et al. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 15 (1998) 2921
78. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 8 (2002) 2045-2052
79. Thompson J.A., Gold P.J., Markowitz D.R., et al. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3 Suppl 1 (1997) S29-S34
80. Del Vecchio M, Bajetta E, Vitali M, et al. Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2849.
81. de Gast G.C., Batchelor D., Kersten M.J., et al. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 88 (2003) 175-180
82. Weber R.W., O'Day S., Rose M., et al. Low does outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha-2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 23 35 (2005) 8892-9000
83. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16 (1998) 1752-1759
84. O'Day S.J., Gammon G., Boasberg P.D., et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor and tamoxifen for patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2752-2761
85. Atkins M.B., Gollob J.A., Sosman J.A., et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFNalpha 2B in patients with metastatic melanoma. Clin Cancer Res 8 (2002) 3075-3081
86. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16 (1999) 1752-1759
87. Atkins MB. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2947.
88. Keilholz U, Punt CJ, Gore S, et al. Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951. Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2848.
89. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17 3 (1999) 968-975
90. Bedikian AY, Johnson MM, Broemeling LD, et al. Prognostic factors determining long term survival of patients with unresectable stage III and stage IV metastatic melanoma (MM) treated with combination therapy or IL-2 based biochemotherapy (BCC). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7544.
91. O'Day S.J., Boasberg P.D., Piro L., et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Can Res 8 (2002) 2775-2781
92. O'Day SJ, Atkins M, Weber J, et al. A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7503.
93. Berkenblit A, Supko J, Ryan DP, et al. STA-4783 in combination with paclitaxel induces heat shock protein 70 (hsp70) in a phase 1 trial. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 2011.
94. For use in combination with Paclitaxel for cancer chemotherapy [investigators brochure STA-4783] (2004), SYNTA Pharmaceuticals Corporation, Lexington (MA)
95. Powderly J, Khan K, Richards J, et al. A 2-stage controlled phase 1/2 study of STA-4783 in combination with Paclitaxel in patients with advanced metastatic melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7561.
96. Jones B., Adams S., Miller G.T., et al. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 102 5 (2003) 1641-1648
97. Redman BG, Ernstoff MS, Gajewski TF, et al. Phase 2 trial of talabostat in Stage IV melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7570.
98. Uprichard MJ, O'Day SJ, Pavlick AC, et al. Phase 2 study of talabostat and cisplatin in Stage IV melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7563.
99. May Jr. K.F., Roychowdhury S., Bhatt D., et al. Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood 105 3 (2005) 114-120
100. Yang Y.F., Zou J.P., Mu J., et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57 18 (1997) 4036-4041
101. Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of fully human anti-cytotoxic t-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 4 (2005) 741-750
102. Ribas A, Bozon VA, Lopez-Berestein G, et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7524.
103. Fischkoff SA, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7525.
104. Enns A., Korb T., Schluter K., et al. Alphavbeta5-integrins mediate early steps of metastasis formation. Eur J Cancer 41 7 (2005) 1065-1072
105. Trikha M., Zhou Z., Nemeth J.A., et al. CNTO 95 has a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110 3 (2004) 326-335
106. Kramer R.H., Vu M., Cheng Y.F., et al. Integrin expression in malignant melanoma. Cancer Metastasis Rev 10 1 (1991) 49-59
107. Hersey P, Sosman J, O'Day S, et al. A phase II randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7507.
108. Millward MJ, Bedikian AY, Conry RM, et al. Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bel-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): analysis of long-term survival. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7505.
109. Kirkwood JM, Bedikian AY, Millward MJ, et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bel-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7506.
110. Reifenberger J., Knobbe C.B., Sterzinger A.A., et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 109 3 (2004) 377-384
111. Eisen T, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7508.
112. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, Carboplatin© and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 7507.
113. Hoshino R., Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 3 (1999) 813-822
114. Abraxane for injectable suspension [patient information enclosure 451031]. Abraxis Oncology. 2005.
115. Hersh EM, O'Day S, Gonzalez R, et al. Open-label, multicenter, phase II trial of ABI-007 in previously treated an previously untreated patients metastatic malignant melanoma. Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7558.